2019
DOI: 10.1167/tvst.8.6.47
|View full text |Cite
|
Sign up to set email alerts
|

Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)

Abstract: PurposeNonarteritic anterior ischemic optic neuropathy (NAION) is the leading cause of sudden optic nerve–related vision loss currently without effective treatment. We evaluated the neuroprotective potential of ocular (topical) delivery of trabodenoson, a selective A1 receptor mimetic, in a rodent model of NAION (rNAION).MethodsDaily topical delivery of 3% trabodenoson or vehicle administered in both eyes 3 days prior to rNAION induction and for 21 days post induction. Retinal appearance and optic nerve head (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 42 publications
0
3
0
Order By: Relevance
“…Although Trabodenoson only moderately suppressed ONH edema (564 ± 14.52 um sem for vehicle vs. 512.15 ±20.12 um sem for Trabodenoson; n = 13), the difference was significant (two-tailed t -test: p = 0.05). Even more importantly, however, Trabodenoson was potently RGC neuroprotective, with RGC loss reduced from 53.2 ± 7.1% sem in vehicle-treated animals to 27.9 ± 6.5% sem RGC loss in animals treated with Trabodenoson ( Figure 7 B; data derived from [ 45 ]). These results also were statistically significant (two-tailed t -test; p = 0.01) and suggest that adenosine receptor agonism is potently neuroprotective, with effects only partly exerted through edema reduction.…”
Section: Resultsmentioning
confidence: 99%
“…Although Trabodenoson only moderately suppressed ONH edema (564 ± 14.52 um sem for vehicle vs. 512.15 ±20.12 um sem for Trabodenoson; n = 13), the difference was significant (two-tailed t -test: p = 0.05). Even more importantly, however, Trabodenoson was potently RGC neuroprotective, with RGC loss reduced from 53.2 ± 7.1% sem in vehicle-treated animals to 27.9 ± 6.5% sem RGC loss in animals treated with Trabodenoson ( Figure 7 B; data derived from [ 45 ]). These results also were statistically significant (two-tailed t -test; p = 0.01) and suggest that adenosine receptor agonism is potently neuroprotective, with effects only partly exerted through edema reduction.…”
Section: Resultsmentioning
confidence: 99%
“…Potentially synergistic combination therapies with PGJ 2 are being explored, though up to this point, none have demonstrated efficacy beyond that of PGJ 2 alone ( 39 ). Daily topical ocular delivery of trabodenoson, a selective adenosine A 1 agonist, was shown to reduce ON edema and preserve RGCs in rNAION, when compared with vehicle ( 40 ). Further, intravitreal injection of ciliary neurotrophic factor (CNTF) was shown to promote RGC survival when administered one day after rNAION induction ( 41 ).…”
Section: Basic and Translational Researchmentioning
confidence: 99%
“…We previously have had success in preventing loss of visual function and retinal ganglion cells (RGC) in our rat model of NAION (rNAION), using intravitreal and systemically administered prostaglandin 15-deoxy 12,14 delta prostaglandin J2 (PGJ 2 ) as well as using topical administration of trabodenoson. 9 However, although delayed administration of these agents has successfully prevented damage in rNAION and pNAION (neuroprotection), it does not restore either optic nerve function or optic nerve integrity (neuroregeneration). 10 We wished to evaluate a neuroregenerative approach in NAION treatment.…”
Section: Introductionmentioning
confidence: 99%